Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9537910.26442/20751753.2021.1.200709ArticlesСтатьиReview ArticleGouty (urate) nephropathyПодагрическая (уратная) нефропатияFominViktor V.ФоминВиктор Викторович

Prof., Corr. Memb. RAS

чл.-кор. РАН, д-р мед. наук, проф., проректор по клинической работе

fomin_v_v_1@staff.sechenov.ruSechenov First Moscow State Medical University (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)15012021231VOL 23, NO1 (2021)ТОМ 23, №1 (2021)111428122021Copyright ©; 2021, Consilium MedicumCopyright ©; 2021, ООО "Консилиум Медикум"2021Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/95379

Clinical variants of kidney damage in gout including asymptomatic disorders of uric acid metabolism are discussed. The risk factor for hyperuricemia and associated kidney damage, clinical variants of gouty nephropathy and approaches to its treatment are presented.

Обсуждаются клинические варианты поражения почек при подагре, в том числе при бессимптомных нарушениях обмена мочевой кислоты. Представлены фактор риска гиперурикемии и связанного с ней поражения почек, клинические варианты подагрической нефропатии и подходы к ее лечению.

gouturate nephropathyhyperuricemiauric acidподаграуратная нефропатиягиперурикемиямочевая кислотаCicerello E. Uric acid nephrolithiasis: an update. Urologia 2018; 85 (3): 93-8.Trinchieri A, Montanari E. Prevalence of renal uric acid stones in the adult. Urolithyasis 2017; 45 (6): 553-62.Ito H, Kotake K, Nomura K, Masai M. Clinical and biochemical features of uric acid nephrolithiasis. Eur Urol 1995; 27 (4): 324-8.Daudon M. Epidemiology of nephrolithiasis in France. Ann Urol (Paris) 2005; 39 (6): 209-31.Trinchieri A, Croppi E, Montanari E. Obesity and urolithiasis: evidence of regional influences. Urolothiasis 2017; 45 (3): 271-8.Robinson PC, Stamp LK. The management of gout. Much has changed. AFP 2016; 45 (5): 299-305.Trinchieri A, Montanari E. Biochemical and dietary factors of uric acid stone formation. Urolithiasis 2018; 46 (2): 167-72.Мухин Н.А., Шоничев Д.Г., Балкаров И.М., и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальном поражении почек. Терапевтический архив. 1999; 71 (6): 12-24Negri AL, Spiwacow R, Del Valle E, et al. Clinical and biochemical profiles of patients with “pure” uric acid nephrolithiasis compares with “pure” calcium oxalate stone formers. Urol Res 2007; 35 (5): 247-51.Spiwacow FR, Del Valle EE, Negri AL, et al. Biochemical diagnosis in 3040 kidney stone formers in Argentina. Urolithiasis 2015; 43 (4): 323-30.Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systemic review of the literature. Curr Opin Rheumatol 2011; 23 (2): 192-202.Blagojevic-Bucknall M, Mallen C, Muller C, et al. The risk of gout in patients with sleep apnea: a matched cohort study. Arthritis Rheumatol 2019; 71 (1): 154-60.Mancia G, Grassi G, Borghi C. Hyperuricemia, urate deposition and association with hypertension. Curr Med Res Opin 2015; 31 (Suppl. 2): 15-9.Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363 (9417): 1277-81.van Westing AC, Kupers LC, Geleijnse JM. Diet and kidney function: a literature review. Curr Hypertens Rep 2020; 22 (2): 14.Щербак А.В., Балкаров И.М., Козловская Л.В., и др. Фибринолитическая активность мочи как показатель поражения почек при нарушениях обмена мочевой кислоты. Терапевтический архив. 2001; 73 (6): 34-7Мухин Н.А., Серов В.В., Варшавский В.А., и др. Некоторые особенности гиперурикемического варианта нефрита. Терапевтический архив. 1986; 58 (6): 43-6Mallat SG, Al Kattar S, Tannios BY, Jurjus A. Hyperuricemia, hypertension and chronic kidney disease: an emerging association. Curr Hypertens Rep 2016; 18 (10): 74.Barkas F, Elisaf M, Liberopoulos E, et al. Uroc acid and incident chronic kidney disease in dyslipidemic individuals. Curr Med Res Opin 2018; 34 (7): 1193-9.Kaewput W, Thongprayoon C, Rangsin R, et al. Association between serum uric acid and chronic kidney disease in patients with hypertension: a multicenter nationwide cross-sectional study. J Evid Based Med 2019; 12 (4): 235-42.Li CC, Chien TM, Wu WJ. Uric acid stones increase the risk of chronic kidney disease. Urolithyasis 2018; 46 (6): 543-6.Tsai CW, Chiu HT, Huang HC, et al. Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analysis. Nephrol Dial Transplant 2018; 33 (2): 231-41.Srivastava A, Kaze AD, McMullan CJ, et al. Uric acid and risk of kidney failure and death in individuals with CKD. Am J Kidney Dis 2018; 71 (3): 362-70.Liu X, Zhai T, Ma R, et al. Effect of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail 2018; 40 (1): 289-97.Zheng R, Yang T, Cheng Q, et al. Serum uric acid concentrations can predict hypertension: a longitudinal, populationbased epidemiological study. Horm Metab Res 2017; 49 (11): 873-9.Scheepers LEJM, Bonen A, Dagnelie PC, et al. Uric acid and blood pressure: exploring the role of uric acid production in The Maastricht Study. J Hypertens 2017; 35 (10): 1968-76.Kansui Y, Matsumura K, Morinaga K, et al. Impact of serum uric acid on incident hypertension in a worksite population of Japanese men. J Hypertens 2018; 36 (7): 1499-505.Zoccali C, Mallamaci F. Uric acid, hypertension and cardiovascular and renal complications. Curr Hypertens Rep 2013; 15 (3): 531-7.Otani N, Toyoda S, Sakuma M, et al. Effect of uric acid on vascular endothelial function from bedside to bench. Hypertens Res 2018; 41 (11): 923-31.Ueno S, Hamada T, Taniguchi S, et al. Effect of Antihypertensive Drugs on Uric Acid Metabolism in Patients with Hypertension: Cross-Sectional Cohort Study. Drug Res (Stuttg) 2016; 66 (12): 628-32.Pongpanich P, Pitakpaibookul P, Takkavatarkan K, et al. The benefits of angiotensin-converting enzyme inhibitors/an-giotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. Int Urol Nephrol 2018; 50 (1): 2261-78.Мухин Н.А., Балкаров И.М., Моисеев С.В., и др. Урикозурическое действие лозартана. Клин. фармакол. тер. 2003; 12 (5): 55-8Ильина А.Е., Барскова В.Г., Насонов Е.Л. Применение лозартана у больных подагрой. Кардиоваскулярная терапия и профилактика. 2008; 7 (2): 34-9Rayner BL, Trinder YA, Baines D, et al. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens 2006; 19 (2): 208-13.Oshira K, Sakima A, Nagata S, et al. Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients. Clin Exp Hypertens 2011; 33 (8): 565-70.Hosoya T, Kuriyama S, Yoshizawa T, et al. Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism. Intern Med 2012; 51 (18): 2509-18.Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology Guidelines for management of gout. Part 1: Systematic pharmacologic and non-pharmacologic therapeutic approaches to hyperuricemia. Arthritic Care Res (Hoboken. 2012; 64 (10): 1431-46.Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology Guidelines for management of gout. Part 2: Therapy and anti-inflammatory prophylaxis of gouty arthritis. Arthritic Care Res (Hoboken) 2012; 64 (10): 1447-61.Stamp LK, Chapman PT, Palmer SC. Allopurinol and kidney function: an update. Joint Bone Spine 2016; 83 (1): 19-24.Badve SV, Pascoe EM, Tiku A, et al.; for the CKD-FIX Study Investigators. Effects of allopurinol on the progression on chronic kindey disease. N Engl J Med 2020; 382: 2504-13.Robinson PC, Stamp LK. The management of gout: much has changed. AFP; 2016: 45 (5): 299-302.Kimura K, Hosoya T, Uchida S, et al.; FEATHER Study Investigators. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis 2018; 72 (6): 798-810.Мухин Н.А., Фомин В.В., Лебедева М.В. Гиперурикемия как компонент кардиоренального синдрома. Терапевтический архив. 2011; 83 (6): 5-13White WB, Saag KG, Becker MA, et al. CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018; 378 (13): 1200-10. DOI: 10.1056//NEJMoa1710895, indexed in PubMed: 29527974.Jansen TLTA, Janssen M. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allo-purinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Clin Rheumatol 2019; 38 (1): 263-5. DOI: 10.1007/s10067-018-4396-4Чазова И.Е., Жернакова Ю.В., Кисляк О.А., и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019; 16 (4): 8-21